Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geert Robaeys

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Acta Gastro-Enterologica Belgica|May 10, 2012
HBV infection in Belgium: results of the BASL observatory of 1,456 HBsAg carriersPierre Deltenre, Wim Laleman, Marc Van Gossum, et al.
Viruses|December 23, 2023
Phylogenetic Analysis of Hepatitis C Virus Infections in a Large Belgian Cohort Using Next-Generation Sequencing of Full-Length GenomesKasper T Christensen, Florian Pierard, David Bonsall, et al.
Scientific Reports|November 3, 2024
Risk factors for SARS-CoV-2 infection and severe COVID-19 in unvaccinated solid organ transplant recipientsCasper Vrij, Kris Bogaerts, Pieter Vermeersch, et al.
The International Journal on Drug Policy|June 19, 2017
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE studyJason Grebely, Olav Dalgard, Evan B Cunningham, et al.
Journal of Hepatology|October 30, 2017
Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in EuropeHannah Fraser, Natasha K Martin, Henrikki Brummer-Korvenkontio, et al.
BMC Public Health|October 27, 2011
Study protocol of KLIMOP: a cohort study on the wellbeing of older cancer patients in Belgium and the NetherlandsLaura Deckx, Doris van Abbema, Katherine Nelissen, et al.
BMC Infectious Diseases|June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE studyEvan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.
JHEP Reports : Innovation in Hepatology|April 8, 2026
A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cellsNicolaas Van Renne, Fleur Ballet, Stijn Van Hees, et al.
The International Journal on Drug Policy|July 8, 2017
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugsJason Grebely, Julie Bruneau, Jeffrey V Lazarus, et al.
The Lancet. Gastroenterology & Hepatology|October 8, 2017
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in EuropeAlison D Marshall, Evan B Cunningham, Stine Nielsen, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Acta Gastro-Enterologica Belgica|May 10, 2012
HBV infection in Belgium: results of the BASL observatory of 1,456 HBsAg carriersPierre Deltenre, Wim Laleman, Marc Van Gossum, et al.
Viruses|December 23, 2023
Phylogenetic Analysis of Hepatitis C Virus Infections in a Large Belgian Cohort Using Next-Generation Sequencing of Full-Length GenomesKasper T Christensen, Florian Pierard, David Bonsall, et al.
Scientific Reports|November 3, 2024
Risk factors for SARS-CoV-2 infection and severe COVID-19 in unvaccinated solid organ transplant recipientsCasper Vrij, Kris Bogaerts, Pieter Vermeersch, et al.
The International Journal on Drug Policy|June 19, 2017
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE studyJason Grebely, Olav Dalgard, Evan B Cunningham, et al.
Journal of Hepatology|October 30, 2017
Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in EuropeHannah Fraser, Natasha K Martin, Henrikki Brummer-Korvenkontio, et al.
BMC Public Health|October 27, 2011
Study protocol of KLIMOP: a cohort study on the wellbeing of older cancer patients in Belgium and the NetherlandsLaura Deckx, Doris van Abbema, Katherine Nelissen, et al.
BMC Infectious Diseases|June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE studyEvan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.
JHEP Reports : Innovation in Hepatology|April 8, 2026
A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cellsNicolaas Van Renne, Fleur Ballet, Stijn Van Hees, et al.
The International Journal on Drug Policy|July 8, 2017
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugsJason Grebely, Julie Bruneau, Jeffrey V Lazarus, et al.
The Lancet. Gastroenterology & Hepatology|October 8, 2017
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in EuropeAlison D Marshall, Evan B Cunningham, Stine Nielsen, et al.
Pageof 6